-
'The sound keeps coming back': children maimed in Ethiopia's Tigray clashes
-
Danish reservists practice war games to respond to 'aggression'
-
Paris Women's Fashion Week: the key trends
-
Bhuvneshwar returns to India's T20 squad for New Zealand tour
-
i-payout Introduces a New Approach to Payments, Closing the Beneficiary Information Gap
-
Asos says probing 'unauthorised activity' after phone alerts
-
New Generation of Crypto Miners Released by ASICID
-
Stocks climb as oil prices retreat under $100 per barrel
-
New investor forecasts LIV Golf teams could be worth $100 mn each
-
Neutrinos: space particles that change our view of universe
-
Shakira, Pique return to court over children visit arrangements
-
'Destined' Djokovic wins China Open, extending unbeaten record
-
Nobel physics prize hails 'ghostly messengers' from space
-
Iceland is 'critical outpost' for security, says Rubio during visit
-
France's Mistral unveils latest model in sovereign AI push
-
Israeli settlers beat AFP photographer covering West Bank
-
Stocks climb as oil prices retreat
-
'Gen Z has risen up': Tens of thousands demand better education in France
-
Vstock Transfer Names Securities Industry Veteran Erica Goodstein General Counsel and Chief Compliance Officer
-
$10 Million and Counting: Hola Prime Hits Major Trader Payout Milestone
-
Four Indonesian seamen return home after Somali pirate ordeal
-
UEFA investigate Ireland-Israel tunnel bustup after spitting claim
-
Crisis-striken Haiti postpones elections
-
Djokovic wins China Open and keeps unbeaten record after de Minaur retires
-
Germany arrests ex-spy chief on suspicion of giving secrets to foreign powers
-
Amsterdam's Rijksmuseum hosts 'homecoming' show for Willem de Kooning
-
Djokovic wins China Open after de Minaur retires
-
World Bank forecasts modest growth for Latin America, highlights climate risks
-
IMF warns cost-of-living shocks cause 'lasting deterioration' in affordability
-
'Afraid for my future': Tens of thousands demand better education in France
-
Alcaraz wins Japan Open for first title since injury return
-
Pakistan PM urges Imran Khan supporters to end protest march
-
'We're working to keep football clean', Turkish minister says
-
Alex Bodi își continuă expansiunea: planuri pentru deschiderea unui showroom ALIX LASERS la București
-
FIFA chief Infantino hit by Norwegian double complaint
-
STARTRADER Adds 20 Stock and ETF CFDs to Its 24/7 Trading Range
-
Exiled Catalan separatist leader Puigdemont cleared to return to Spain
-
Bulgaria searches for missing crew after drones hit more Black Sea ships
-
Stock markets climb as oil prices retreat
-
Alcaraz wins Japan Open for first title since return from injury
-
'No future': Thousands mass in France for high school protests
-
India, Qatar, S.Africa among nations who want to host 2036 Olympics
-
Nobel physics prize honours work on 'ghostly messengers' from outer space
-
Muchova squeaks out win over Osaka to reach China Open quarter-finals
-
Bulgaria searches for missing crew after drones hit two more ships in Black Sea
-
Kenya reports first-ever Ebola death
-
Le Pen vows drastic cost savings to prevent French 'default'
-
Tennis world No.1 Sinner's season over due to knee injury
-
'Eats through a straw': French teens wounded in high school protests
-
Yemen's Houthis claim attack on Riyadh airport, deny losing territory
Bayer gets preliminary approval for weedkiller class settlement
German agrichemical giant Bayer said Wednesday that a US judge had granted preliminary approval for a multi-billion-dollar class settlement proposed by its subsidiary Monsanto over claims the Roundup weedkiller causes blood cancer.
Bayer announced last month that Monsanto had put forward the settlement of up $7.25 billion, seeking to draw a line under years of costly litigation.
Under the proposed agreement, Monsanto would make a series of declining annual payments for up to 21 years.
Bayer has spent billions of dollars settling thousands of cases linked to Roundup since it acquired the weedkiller's producer, the US agrichemical group Monsanto, in 2018.
The International Agency for Research on Cancer considers glyphosate, one of Roundup's ingredients, a probable human carcinogen, but Bayer says scientific studies and regulatory approvals show the weedkiller is safe.
Announcing the latest development Wednesday, Bayer said a judge in Missouri had granted preliminary approval for the settlement.
"This is the first major step in putting this settlement into effect, and we remain confident that the long-term and well-financed class settlement plan, which is supported by leading plaintiffs' law firms, warrants final approval by the court," said a statement from the Leverkusen-based group.
People potentially covered by the settlement will now be notified and will have 90 days to opt out or file objections, Bayer said.
The court will then decide whether to grant final approval of the settlement, which will be subject to potential appeals.
- 'Right approach' -
Getting the settlement through would mark a milestone for Bayer, which otherwise faces a potentially still long and expensive legal road. About 67,000 Roundup cases are still outstanding.
It said in February it had set aside 11.8 billion euros to deal with litigation as of September 2025, up from 7.8 billion euros previously.
Bayer said then that it expected litigation payouts of about five billion euros for 2026 "on a first estimate". The settlements did not contain or imply any admission of liability or wrongdoing, the group said.
The group earlier Wednesday announced it made a loss of 3.62 billion euros ($4.20 billion) in 2025 after it booked extra charges related to weedkiller claims.
The loss was bigger than the 2.55 billion euros the firm lost in 2024.
The settlement was necessary despite the Supreme Court agreeing to hear Bayer's appeal against damages to a Missouri man who claims Roundup caused his cancer, company boss Bill Anderson said, warning that the firm otherwise faced being bogged down in lawsuits.
"This settlement agreement is the right approach at the right time," he said.
"The company needs to move on. This has been a huge drag on Bayer for almost a decade."
R.Halabi--SF-PST